EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Underrepresentation of Hispanics in clinical trials for liver cancer in the United States over the past 20 years

Cecilia Monge iD, Tim F Greten iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.6814 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Cecilia Monge und 1 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes …. Hauptthemen laut MEDLINE: Liver Neoplasms, Hispanic or Latino. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NCI Intramural funidng, WInn CDA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Accurate representation of racial and ethnic population subgroups in clinical trials is fundamental to ensure universal effectiveness of new therapies as well as to decrease disparities in oncology care.

Objective

To determine whether Hispanic people are underrepresented in Phase I and II clinical trials for liver cancer in the United States.

Participants

A database search was performed in clinicaltrials.gov for interventional liver cancer studies based only in the US with reported results from September 1, 2002, to February 1, 2023. A total of 37 trials with 963 total patients met inclusion criteria and were included for further analysis. Proportion of total patients by race/ethnicity was calculated for non‐Hispanic white, non‐Hispanic black, Asian, Hispanic, and American Indian/Alaska Native subpopulations. The age‐adjusted incidence rates of liver and intrahepatic bile duct were acquired from the National Cancer Institute, Surveillance, Epidemiology, and End Results Program.

Results

Liver cancer incidence rates (per 100,000 people) were highest in Indians/Alaska Native people (18.8 cases) followed by Hispanic people (15.1 cases), then Asian people (12.5 cases), then non‐Hispanic black people (11 cases), and non‐Hispanic white people (7.5 cases). From a total of 91 phase I or II clinical trials for liver cancer in the US, 41% reported race/ethnicity enrollment data; among these, 62.8% of patients were non‐Hispanic White, 15.9% were non‐Hispanic black, 8.8% were Hispanic, 12.7% Asian, and 0.5% American Indian/Alaska Native. Conclusions and Relevance Less than half of phase I or II clinical trials for liver cancer in the US in the last 20 years reported race/ethnicity data to clinicaltrials.gov . Compared to the relative incidence rate of liver cancer, non‐Hispanic black people and Hispanic people are underrepresented in these clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsHispanic or LatinoHumansUnited StatesIncidenceMaleFemaleClinical Trials, Phase I as TopicSEER ProgramClinical Trials, Phase II as TopicClinical Trials as Topic

Stichwörter der Autor:innen

SEERcholangiocarcinomaclinical trialsdiversityliver cancer

Autor:innen und Institutionen

  • Gastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Cecilia Monge, Tim F Greten

Förderung

  • Intramural NIH HHS
  • NCI Intramural funidng
  • WInn CDA

Zitieren

APA

Monge, C., & Greten, T. F. (2024). Underrepresentation of Hispanics in clinical trials for liver cancer in the United States over the past 20 years. Cancer Medicine. https://doi.org/10.1002/cam4.6814

Vancouver

Monge C, Greten TF. Underrepresentation of Hispanics in clinical trials for liver cancer in the United States over the past 20 years. Cancer Medicine. 2024. doi:10.1002/cam4.6814

BibTeX
@article{Monge2024,
  author = {Monge, Cecilia and Greten, Tim F},
  title = {Underrepresentation of Hispanics in clinical trials for liver cancer in the United States over the past 20 years},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6814}
}
Kostenlos starten →